Navigation Links
Acute Pain Global Clinical Trials Review, H2, 2013
Date:11/27/2013

tics 39
Cubist Pharmaceuticals, Inc. 40
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. 40
Shire Plc 41
Clinical Trial Overview of Shire Plc 41
AcelRx Pharmaceuticals, Inc. 42
Clinical Trial Overview of AcelRx Pharmaceuticals, Inc. 42
Luitpold Pharmaceuticals, Inc. 43
Clinical Trial Overview of Luitpold Pharmaceuticals, Inc. 43
IPCA Laboratories Limited 44
Clinical Trial Overview of IPCA Laboratories Limited 44
Grunenthal GmbH 45
Clinical Trial Overview of Grunenthal GmbH 45
Troikaa Pharmaceuticals Ltd. 46
Clinical Trial Overview of Troikaa Pharmaceuticals Ltd. 46
Wockhardt UK Holdings Limited 47
Clinical Trial Overview of Wockhardt UK Holdings Limited 47
Ardent Pharmaceuticals Inc 48
Clinical Trial Overview of Ardent Pharmaceuticals Inc 48
A. Menarini AG 49
Clinical Trial Overview of A. Menarini AG 49
AbbVie Inc. 50
Clinical Trial Overview of AbbVie Inc. 50
Mallinckrodt plc 51
Clinical Trial Overview of Mallinckrodt plc 51
Clinical Trial Overview of Top Institutes / Government 52
Montefiore Medical Center 52
Clinical Trial Overview of Montefiore Medical Center 52
Tehran University of Medical Sciences 53
Clinical Trial Overview of Tehran University of Medical Sciences 53
University Hospital, Toulouse 54
Clinical Trial Overview of University Hospital, Toulouse 54
Ahvaz Jundishapur University of Medical Sciences 55
Clinical Trial Overview of Ahvaz Jundishapur University of Medical Sciences 55
The Samueli Institute 56
Clinical Trial Overview of The Samueli Institute 56
The University of Sydney 57
Clinical Trial Overview of The University of Sydney 57
Ullevaal University Hospital 58
Clinical Trial Overview of Ullevaal University Hospital 58
Leiden University Medical Center 59
Clin
'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
2. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
3. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
4. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
7. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
8. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
9. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
10. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
11. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... VANCOUVER, March 31 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... announced it has completed an Amended and Restated ... International Inc. (Baxter). As consideration for the Amended ... receive $25 million. , Angiotech and Baxter initially ...
... AG (VSE: ICLL) today announced that it will host ... and Drug Administration,s (FDA) approval of IXIARO(R), a new ... initial target for use of Intercell,s vaccine - the ... - will be adult travelers and military personnel who ...
... 31 DOR BioPharma, Inc. (OTC Bulletin Board: DORB) ... announced its financial results for 2008. DOR,s revenues for ... in 2007. The increase was due primarily to ... resulting achievement of certain research and development milestones with ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 2Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 3Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 4Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 2Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 5
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
(Date:4/23/2014)... their mid-thirties and forties, face a devastating prognosis: ... decades. "Mutant" protein clusters, long blamed for the ... primary focus of therapies in development by pharmaceutical ... Gerardo Lederkremer and Dr. Julia Leitman of Tel ... in collaboration with Prof. Ulrich Hartl of the ...
(Date:4/23/2014)... NY. (Apr. 23, 2014) People who have had ... to restore neurological function. However, a study conducted in ... of Cell Transplantation , but is currently freely ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group of ... (PBSCs) injected directly into the brain and a similar ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
... Scientists at the Zucker Hillside Hospital campus of the ... markers that can increase a persons risk for schizophrenia. ... of the National Academy of Sciences, the research team ... be inherited in a recessive manner. A recessive trait ...
... have used ultraviolet light to sculpt three-dimensional microparticles ... and tissue engineering. For example, they could be ... molecules, such as DNA, or to release drugs ... control over the size, shape and texture of ...
... Journal of Lipid Research (Vol. 48, No. 12) ... Disease Increases Progression of Atherosclerosis, Breaking the Vicious Cycle ... Genetic Variants Affect Weight-Associated Cholesterol Metabolism ... alter how the body adjusts cholesterol metabolism in response ...
Cached Biology News:Feinstein researchers develop new genetic method and identify novel genes for schizophrenia 2MIT sculpts 3-D particles with light 2Story ideas from the Journal of Lipid Research 2Story ideas from the Journal of Lipid Research 3
Request Info...
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Biology Products: